BIAF • NASDAQ
bioAffinity Technologies, Inc.
$5.64
Stock Details
| Market Cap | 2,362,432 |
|---|---|
| Day Change | -0.52 (-8.44%) |
| Volume | 35,196,533 |
| Avg Volume | 2,075,727 |
| Price Range | 4.56-80.7 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NASDAQ |
Company Profile
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Financial Overview
| 52 Week High | 80.7 |
|---|---|
| 52 Week High Date | 2026-03-23 |
| 52 Week Low | 4.56 |
| 52 Week Low Date | 2026-08-31 |
| 10D Avg Trading Vol | 0.20659 |
| YTD Price Return Daily | -65.7627 |
| MTD Price Return Daily | -7.622 |
Cash Flow
| TTM/Share | -0.94598 |
|---|---|
| Annual/Share | -2.0871 |
| Quarterly/Share | -1.7043 |
Price-to-Earnings
| Annual Ratio | 2.6032 |
|---|---|
| Quarterly Ratio | 1.4418 |
| TTM |
Revenue
| 3Y Growth | |
|---|---|
| 5Y Growth | |
| Annual/Share | 18.99 |
| TTM/Share | 1.129 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -8.663 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 1.9068 |
|---|---|
| Annual Ratio | 0.7294 |
| TTM | 1.3537 |